Screening, Synthesis, and Evaluation of Novel Isoflavone Derivatives as Inhibitors of Human Golgi β-Galactosidase
作者:Kazuki Miura、Chihiro Onodera、Motonari Takagi、Ryosuke Koyama、Takako Hirano、Toshiyuki Nishio、Wataru Hakamata
DOI:10.1248/cpb.c20-00194
日期:2020.8.1
system, in vitro assay, and cytotoxicity assay. An isoflavone derivative was identified among the final Golgi β-galactosidase inhibitor compound hits. Molecular docking simulations were performed to redesign the isoflavone derivative into a more potent inhibitor, and six designed derivatives were then synthesized. One of the derivatives, ARM07, exhibited potent inhibitory activity against β-galactosidase
基因GLB1和GALC分别编码GLB1同工型1和半乳糖脑苷脂酶,它们在人溶酶体中表现出β-半乳糖苷酶活性。已报道GLB1同工型1在罕见的溶酶体贮积病中起作用。此外,其β-半乳糖苷酶活性是衰老和衰老细胞中使用最广泛的生物标记。因此,它被称为衰老相关的β-半乳糖苷酶。半乳糖脑苷脂酶在克拉伯病中起作用。我们之前曾报道过人类细胞的高尔基体中有一种新型的β-半乳糖苷酶活性。然而,无法鉴定出负责此活性的蛋白质。抑制剂衍生的化学探针可以用作识别负责蛋白质的强大工具。在这项研究中,我们首先为高尔基β-半乳糖苷酶抑制剂构建了基于细胞的高通量筛选(HTS)系统,体外测定和细胞毒性测定。在最终的高尔基体β-半乳糖苷酶抑制剂化合物中发现了异黄酮衍生物。进行分子对接模拟以将异黄酮衍生物重新设计为更有效的抑制剂,然后合成了六种设计的衍生物。衍生物之一ARM07对β-半乳糖苷酶表现出有效的抑制活性,IC 50值为14.8